Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
66 hedge funds and large institutions have $40.6M invested in Asterias Biotherapeutics Inc. Series A in 2016 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 8 reducing their positions, and 9 closing their positions.
11,050% more call options, than puts
Call options by funds: $223K | Put options by funds: $2K
175% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 8
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
14% more capital invested
Capital invested by funds: $35.6M → $40.6M (+$4.99M)
3% more funds holding
Funds holding: 64 → 66 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$398K |
| 2 |
State Street
Boston,
Massachusetts
|
+$298K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$262K |
| 4 |
Morgan Stanley
New York
|
+$258K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$309K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$295K |
| 3 |
Goldman Sachs
New York
|
-$210K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$151K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$64K |
AST Hedge Fund Activity: Q4 2016 in Review
66 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q4 2016, worth a combined $40.6M — up 14% from $35.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AST positions and 9 closed out — a net gain of 3 holders — while 22 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $398K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $309K sold.
- 66 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q4 2016, up from 64 in Q3 2016.
- Funds reported $40.6M of Asterias Biotherapeutics Inc. Series A stock for Q4 2016, up 14% quarter-over-quarter.
- 12 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q4 2016 and 9 closed out, a net change of +3 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $398K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q4 2016 was Virtu KCG Holdings, an estimated $309K sold.
Based on aggregated 13F filings for Q4 2016.